drugset / Trial / NCT02630511

Asthma Exacerbations and Vascular Function

NCT02630511

Completed 52 enrolled University of Alberta
RandomizedCrossoverDouble-blindBasic science

Summary

Although asthma is a disease of the airways, research is now showing that asthmatics are more likely to develop cardiovascular disease (CVD) compared to non-asthmatics. Vascular dysfunction is seen in people at high risk of CVD and has been linked to inflammation. During an asthma attack, levels of inflammation in the whole body increase, which could potentially explain why asthmatics are at increased risk of CVD. By exercising, people can change the amount of inflammation in their bodies, improve vascular function, and thereby reduce the risk of CVD. In the proposed study the investigators will assess if asthma attacks lead to increased risk of CVD by evaluating inflammatory levels and vascular function before and after asthma attacks. The investigators will also evaluate if exercise reduces the cardiovascular risk following asthma attacks. The results from this study will help in understanding why asthmatics are at increased risk of CVD.

Timeline

Start
2015-12
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 635 mg Inhaled
Subject Methacholine Diagnostic / imaging agent 16 mg/ml Inhaled

Indications